Daniel M. Anderson, MD, MPH
Principal Investigator, Metro-Minnesota Community Oncology Research Consortium

Affiliations/other offices held: Assistant Professor, Department of Hematology, Oncology and Transplantation, University of Minnesota.

Joined the Institute: 2003

Education and training: MD, University of Minnesota; residency in internal medicine, Hennepin County Medical Center; fellowship in hematology/oncology, University of Minnesota; MPH in epidemiology, University of Minnesota.

Overview/research interests: Dr. Anderson serves as the Principal Investigator for the Metro-Minnesota Community Oncology Research Consortium. Additionally, he is a co-chair of the Community Oncology Committee at the Alliance for Clinical Trials in Oncology. He became interested in working with people with cancer because of the unique relationships he has developed with them. He also enjoys the intellectual challenge of working with patients who have blood and clotting disorders. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research and Minnesota Society of Clinical Oncology.

  • Principal Investigator, Metro-Minnesota Community Oncology Research Consortium, Cancer Research Center 2003 -
  • Publications While At HealthPartners
    selected publications
    Journal Article
  • PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal of Clinical Oncology. 2024
  • Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
    Commun Med (Lond). 2023
  • Validation of immunotherapy response score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
    Cancer Res Commun. 2023
  • Organizational characteristics and smoking cessation support in community-based lung cancer screening programs
    Journal of the American College of Radiology. 2022
  • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
    Lancet Oncology. 2021
  • Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
    European Journal of Cancer. 2021
  • Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples
    JCO precision oncology. 2021
  • A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: the MAESTRO study
    Cancer. 2020
  • Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial
    Journal of Thrombosis and Haemostasis. 2020
  • Randomized trial of lenalidomide versus observation in smoldering multiple myeloma
    Journal of Clinical Oncology. 2020
  • Sequencing ipilimumab immunotherapy before or after chemotherapy (nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF wild-type) metastatic malignant melanoma: results of a study of Academic and Community Cancer Research United (ACCRU) RU261206I
    American Journal of Clinical Oncology. 2020
  • A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
    Cancer. 2019
  • Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
    Blood. 2018
  • The financial toll of cancer therapy: developing ways to help the patient
    Minn Physician. 2017
  • Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
    Annals of Oncology. 2016
  • A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia
    American Journal of Hematology. 2015
  • North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes
    Menopause (New York, N.Y.). 2015
  • NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status
    Journal of Thoracic Oncology. 2014
  • N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
    Annals of Oncology. 2010
  • Impact of chemotherapy in women with metastatic breast cancer diagnosed 1990-2003
    Clinical Breast Cancer. 2007
  • presentations
    full name
  • Daniel M. Anderson, MD, MPH
  • located in facility
    Quick Info
    More Info